These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 33118321)

  • 1. Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease.
    Gono T; Masui K; Nishina N; Kawaguchi Y; Kawakami A; Ikeda K; Kirino Y; Sugiyama Y; Tanino Y; Nunokawa T; Kaneko Y; Sato S; Asakawa K; Ukichi T; Kaieda S; Naniwa T; Okano Y; Kuwana M;
    Arthritis Rheumatol; 2021 Apr; 73(4):677-686. PubMed ID: 33118321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y; Fu Q; Wang R; Guo Q; Bao C
    J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
    Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
    Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
    Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
    Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
    Kaieda S; Gono T; Masui K; Nishina N; Sato S; Kuwana M;
    PLoS One; 2020; 15(6):e0234523. PubMed ID: 32525903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease.
    Zhu Y; Wang L; Sun Y; Wang J; Lv C; You H; Xu L; Wang F; Zhang M; Tan W; Ke Y
    Clin Exp Rheumatol; 2022 Feb; 40(2):292-297. PubMed ID: 34874831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment mortality risk prediction model in patients with polymyositis/dermatomyositis-associated interstitial lung disease.
    Gui X; Li W; Jiang H; Wang R; Yu M; Zhao T; Ma M; Ding J; Jin Z; Qiu Y; Qiu X; Zhang Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xin X; Xiao Y
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38663883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
    Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
    Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KL-6 is a long-term disease-activity biomarker for interstitial lung disease associated with polymyositis/dermatomyositis, but is not a short-term disease-activity biomarker.
    Hanaoka M; Katsumata Y; Kawasumi H; Kawaguchi Y; Yamanaka H
    Mod Rheumatol; 2019 Jul; 29(4):625-632. PubMed ID: 30484723
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease.
    Hozumi H; Fujisawa T; Enomoto N; Nakashima R; Enomoto Y; Suzuki Y; Kono M; Karayama M; Furuhashi K; Murakami A; Inui N; Nakamura Y; Mimori T; Suda T
    J Rheumatol; 2017 Sep; 44(9):1394-1401. PubMed ID: 28711881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis.
    Fathi M; Barbasso Helmers S; Lundberg IE
    J Intern Med; 2012 Jun; 271(6):589-97. PubMed ID: 21950266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature review.
    Wang Y; Chen S; Lin Z; Lin J; Xie X; Lin Q; Du G; Huang X; Matucci-Cerinic M; Furst DE
    Clin Rheumatol; 2019 May; 38(5):1433-1436. PubMed ID: 30746580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality Risk Stratification Using Cluster Analysis in Patients With Myositis-Associated Interstitial Lung Disease Receiving Initial Triple-Combination Therapy.
    Gono T; Masui K; Sato S; Kuwana M
    Front Med (Lausanne); 2022; 9():883699. PubMed ID: 35615085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies.
    Asakawa K; Yoshizawa K; Aoki A; Kimura Y; Tanaka T; Ohashi K; Hayashi M; Kikuchi T; Sato S; Takada T
    Clin Rheumatol; 2020 Jul; 39(7):2171-2178. PubMed ID: 32056068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis/dermatomyositis-interstitial lung disease.
    Matsuda S; Kotani T; Ishida T; Fukui K; Fujiki Y; Suzuka T; Nagai K; Hata K; Shoda T; Isoda K; Ito Y; Makino S; Takeuchi T; Arawaka S
    Rheumatology (Oxford); 2020 Feb; 59(2):310-318. PubMed ID: 31321420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease.
    Takanashi S; Nishina N; Nakazawa M; Kaneko Y; Takeuchi T
    Rheumatology (Oxford); 2019 Jun; 58(6):1034-1039. PubMed ID: 30624752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of Coagulation Markers for the Prediction of Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis.
    Sagawa T; Kida T; Inaba T; Yokota I; Sagawa R; Kasahara A; Kaneshita S; Inoue T; Nagahara H; Fujioka K; Wada M; Kohno M; Kawahito Y
    Lung; 2019 Aug; 197(4):437-442. PubMed ID: 31240390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.